Event Brief
SIL204 enters Phase 2/3 for KRAS-driven tumors
Filed: Aug 05, 2026 at 8:11 AM ET
Summary: SIL204 advanced into Phase 2/3 evaluation and began its first clinical trial at Tel Aviv Sourasky Medical Center.
WHO: Silexion
WHAT: SIL204 advanced into Phase 2/3 clinical evaluation and began its first clinical trial at Tel Aviv Sourasky Medical Center.
WHEN: Aug 05, 2026 at 10:38 AM ET
WHERE: Israel
WHY: Cause not yet established.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →